Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121165 | 0.90 | GAA (0.47) | LMNAKMT2ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL5119573 | 0.88 | KMT2A (0.39) | KMT2ASMN1; SMN2HTTALDH1A1GAA | |
| SCHEMBL5119685 | 0.87 | RAB9A (0.39) | LMNAKMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL1457213 | 0.86 | KMT2A (0.43) | LMNAKMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL5122782 | 0.86 | MEN1 (0.47) | LMNAKMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL5121677 | 0.86 | LMNA (0.41) | LMNAKMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL5126307 | 0.85 | MAPT (0.41) | KMT2AHTTMAPTMEN1KDM4E | |
| SCHEMBL5111849 | 0.85 | MAPT (0.52) | LMNAKMT2AHTTMAPTALDH1A1 | |
| SCHEMBL5111409 | 0.83 | POLB (0.49) | LMNAKMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5119238 | 0.82 | ALDH1A1 (0.46) | LMNAKMT2ASMN1; SMN2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | LMNA 421/4885KMT2A 4068/4885SMN1; SMN2 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.